Recombinant canstatin inhibits tumor growth in an orthotopic AT-84 oral squamous cell carcinoma model.
The inhibitory effect of recombinant canstatin on tumor growth was investigated using an orthotopic oral squamous cell carcinoma (AT-84 cells) animal (C3H/HeN) model. Recombinant canstatin from stably transfected Drosophila S2 cells was purified to homogeneity using a simple one-step Ni NTA affinity fractionation. In our oral cancer model, the final volume and weight of tumors in groups treated with purified canstatin were both reduced to 44% of values for a control group treated with PBS. Blood or lymphatic vessel densities of tumors in the canstatin-treated group were reduced to 72% and 44% of control group values, respectively. Recombinant canstatin at 20 microg/ml effectively inhibited tube formation in HUVEC and lymphatic endothelial cells. Our results show that recombinant canstatin has anti-tumoral effects against primary oral squamous cell carcinoma.
Hwang-Bo
Jeon
J
Department of Genetic Engineering and Graduate School of Biotechnology, Kyung Hee University, Suwon 446-701, Korea.
Yoo
Ki Hyun
KH
Jeong
Han-Sin
HS
Chung
In Sik
IS
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D011994:Recombinant Proteins / Q000008:administration & dosage*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011994:Recombinant Proteins